Recently, the advent of immune checkpoint inhibitor therapy and its striking efficiency for MMR-deficient tumors, regardless of tumor site [49,50], prompted demand for the detection of MMR deficiency in various tumor types. The gene discussed is MRC1; the disease is neoplasm.